GW’s Epidiolex results are worth mentioning

Whenever one of my biotech companies have good news. It almost always makes me smile. Yesterday it was GW. The shares of GW Pharmaceuticals (GWPH) are soaring on news that its cannabis-derived drug significantly diminished the seizure amount in children with a rare form of epilepsy in a phase-three trial. Epidiolex…

Continue reading

OCAT – Q3 2015 – Results are in.

View: Annual Data | Quarterly Data All numbers in thousands Period Ending Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Total Revenue 84   39   39   39   Cost of Revenue 16 16 16 16 Gross Profit 69   24   24   24   Operating Expenses Research Development 4,336 3,544 3,378…

Continue reading